All
“Apply to Affected Area BID x 2 Weeks Then PRN”
Step therapy can delay appropriate care and potentially worsen patients' conditions, writes Dermatology Times Spring Editor in Chief Aaron Farberg, MD.
The Road to Relief: Navigating a Personal Atopic Dermatitis Journey
Kristine Kucera, PA-C, MPAS, DHS, discusses the atopic dermatitis patient experience alongside one of her patients, Mickey Bryson.
Disease Severity and Age Can Affect Impact of AD
A study out of Japan found the burden on patients with atopic dermatitis and their caregivers can increase with age and disease severity.
Day 2 Recap: 2024 Revolutionizing Alopecia Areata, Vitiligo, and Eczema Conference
Catch up on coverage from the last day of the 2024 Revolutionizing Alopecia Areata, Vitiligo, and Eczema Conference in Chicago, Illinois.
Late-Breaker: Upadacitinib Demonstrates Superiority Over Dupilumab in All Ranked Secondary End Points of Head-to-Head AD Study
The phase 3b/4 LEVEL-UP study assessed adolescents and adults with moderate to severe atopic dermatitis.
Late-Breaker: Roflumilast Cream 0.15% Demonstrates Continued Improvement in AD Symptoms Through 56 Weeks
Roflumilast cream 0.15% is being evaluated for patients with mild to moderate atopic dermatitis down to 6 years.
Addressing Itch and Remission in Atopic Dermatitis
Raj Chovatiya, MD, PhD, discusses how approved AD therapeutics currently address itch and whether any therapeutics will eventually have a remittive effect.
MoonLake Immunotherapeutics Announces FDA, EMA Support of Furthering Phase 3 Sonelokimab for PsA
The phase 3 IZAR program will evaluate the efficacy and safety of sonelokimab in patients with psoriatic arthritis for a 1 year duration.
Looking Ahead to Advancements in Vitiligo and Atopic Dermatitis
David Rosmarin, MD, shares key points from phase 3 data of ruxolitinib for vitiligo, as well as highlights the potential for targeting the STAT pathway in upcoming atopic dermatitis therapeutics.
Exploring New Pathways in Atopic Dermatitis
Melinda Gooderham, MSc, MD, FRCPC, discusses potential new biologics for atopic dermatitis that target IL-22, IL-33, OX40, and more.
Promising Results in Phase 2 Trial of ProSilic
The trial reported complete hair regrowth for a number of participants, with 76% of a partial cohort meeting the primary endpoint of 30% improvement.
Comparing AD Guidelines From Around the World
Robert Sidbury, MD, MPH, addresses the similarities and differences between the AAD’s recent atopic dermatitis guidelines and other guidelines from various groups and countries.
FDA Approves Expanded Use of Tirbanibulin for Actinic Keratosis
Phase 3 clinical trial results showed that the safety and tolerability profiles were consistent with those observed in the original pivotal trials.
Safety vs Efficacy: What AD Treatments Can Be Used in Pediatric Patients?
Amy Paller, MD, reviews the various types of therapeutics available and coming soon for pediatric atopic dermatitis and how she decides what treatment approach is best for each patient.
Day 1 Recap: 2024 Revolutionizing Alopecia Areata, Vitiligo, and Eczema Conference
Catch up on coverage from the first day of the 2024 Revolutionizing Alopecia Areata, Vitiligo, and Eczema Conference in Chicago, Illinois.
What’s New in Devices for Vitiligo?
Karan Lal, DO, dives into the benefits of combination therapy for vitiligo with topicals and devices.
Don’t Forget to Address Autoimmune Comorbidities of Atopic Dermatitis
Jonathan Silverberg, MD, PhD, MPH, presented his tips for effectively treating atopic dermatitis without worsening autoimmune comorbidities.
Upadacitinib Demonstrates Continued Improvements in Patients With Moderate to Severe AD Through 140 Weeks
Improvements in patient-reported outcomes were higher among patients treated with upadacitinib 30mg versus 15mg.
Ritlecitinib Shows Promising Results in Long-Term Trial
Researchers found patients with less than 95% hair loss at baseline reached median SALT score 2.4 or less, reflecting almost complete hair regrowth.
Considerations for Topical Therapeutics and Clinical Excellence in Vitiligo
Nanette Silverberg, MD, shares data on the efficacy of on- and off-label therapeutics for vitiligo, as well as the importance of communication with patients to promote clinical excellence.
Serum CXCL10 Levels Decreased With Use of Ruxolitinib Cream In Patients With Vitiligo
Data from the TRuE-V mechanism of action study was presented in a poster at the 2024 RAVE Conference.
A RAVE Upgrade: Previewing Revolutionizing Alopecia Areata, Vitiligo, and Eczema
Jonathan Silverberg, MD, PhD, MPH, shares insights into the change of this year’s meeting and the benefit of additional disease states.
Spotlighting Vitiligo: New Innovations to be Presented at RAVE 2024
Nanette Silverberg, MD, shares her excitement about the inclusion of vitiligo at this year’s RAVE meeting.
What to Expect at the 2024 Revolutionizing Alopecia Areata, Vitiligo, and Eczema Conference
The inaugural RAVE conference begins today in Chicago, Illinois.
Summer Highlights to Improve Patient Care
The June issue of Dermatology Times features a collection of articles related to e-cigarette use and skin, Acne Awareness Month, and more.
Introducing Karan Lal, DO, MS, FAAD: Dermatology Times' Newest Editorial Advisory Board Member
Karan Lal, DO, MS, FAAD, is a double-board certified pediatric and cosmetic dermatologist at Affiliated Dermatology in Scottsdale, Arizona.
Global Hidradenitis Suppurativa Atlas Produces Report Aimed at Advancing Knowledge and Awareness of HS
Henry Lim, MD, discusses key findings and areas of improvement identified by the report, as well as his hopes for HS treatment moving forward.
VYNE Therapeutics Initiates Phase 2b Trial of BET Inhibitor VYN201 for Vitiligo
The primary efficacy endpoint is the proportion of subjects achieving at least a 50% improvement in the Facial Vitiligo Area Scoring Index.
PODCAST: From Infection to Innovation - The Turn Therapeutics Story
Turn Therapeutics' Bradley Burnam recently spoke with Dermatology Times.
POLL: Which Specialties Have You Referred Patients To, Ensuring They Receive Multidisciplinary Care Surrounding Their Skin Condition?
Click here to answer today's poll and read more about providing patients with multidisciplinary care.